Zika virus (ZIKV) is a flavivirus mainly transmitted to humans through the bite of infected Aedes aegypti mosquitoes. First isolated in Uganda in 1947, ZIKV was shown to circulate in enzootic sylvatic cycles in Africa and Asia for at least half a century before the first reported human epidemic occurred in 2007 on the Pacific island of Yap, Micronesia. Subsequently, larger ZIKV outbreaks were recorded in French Polynesia and other South Pacific islands during 2013-2014. In 2015, ZIKV reached Brazil from where it rapidly spread across the Americas and the Caribbean, causing hundreds of thousands of human cases. The factors that have fueled the explosiveness and magnitude of ZIKV emergence in the Pacific and the Americas are poorly understood. Reciprocally, the lack of major human epidemics of ZIKV in regions with seemingly favorable conditions, such as Africa or Asia, remains largely unexplained. To evaluate the potential contribution of vector population diversity to ZIKV epidemiological patterns, we established dose-response curves for eight field-derived Ae. aegypti populations representing the global range of the species, following experimental exposure to six low-passage ZIKV strains spanning the current viral genetic diversity. Our results reveal that African Ae. aegypti are significantly less susceptible than non-African Ae. aegypti across all ZIKV strains tested. We suggest that low susceptibility of vector populations may have contributed to prevent large-scale human transmission of ZIKV in Africa.
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Main text:
Zika virus (ZIKV) is a mosquito-borne virus (genus: Flavivirus; family: Flaviviridae) mainly transmitted among humans through the bite of infected Aedes aegypti mosquitoes [1]. ZIKV was first isolated in 1947 from the serum of a sentinel rhesus monkey in the Zika Forest of Uganda [2] . Subsequently, serological evidence and virus isolation from humans and mosquitoes revealed ZIKV circulation in enzootic sylvatic cycles both in Africa (African ZIKV lineage) and Asia (Asian ZIKV lineage). For at least half a century following its discovery, ZIKV did not cause any recorded human epidemic, as less than 20 human cases were documented between 1947 and 2006 [1,3].
The first ZIKV human outbreak occurred in 2007 on the Pacific island of Yap in the Federated States of Micronesia, Oceania where ZIKV (Asian lineage) infected 73% of the islanders [4] . ZIKV outbreaks were then reported in French Polynesia [5] and other South Pacific islands during 2013-2014 [6] . Whereas human ZIKV infection is usually asymptomatic or results in a self-limiting mild illness, for the first time it was associated with severe neurological complications such as congenital microcephaly and Guillain-Barré syndrome [7, 8] . In 2015, ZIKV reached Brazil and rapidly spread across South, Central, and North America and the Caribbean [3] , causing an estimated 583,451 suspected and 223,477 confirmed cases between 2015 and 2017 [9] .
To date, the factors that promoted the rapid emergence, dispersal and apparent increase in pathogenicity of ZIKV in the Pacific and the Americas are not fully understood. They may include a number of mechanisms, including viral mutations increasing transmission from humans to mosquitoes, enhancing fetal microcephaly, and modulating the host immune response [10] [11] [12] [13] [14] . Reciprocally, the lack of major epidemics in regions such as Africa and Asia, where conditions are seemingly favorable, is still largely unexplained. It has been hypothesized that this may reflect higher levels of background immunity conferred by cross-protective antibodies against ZIKV-related viruses [15] .
Besides ZIKV evolution or contrasted human background immunity, the potential contribution of vector population genetic diversity to ZIKV epidemiological patterns may have been overlooked [15] . Earlier studies using field-derived Ae. aegypti populations demonstrated significant variation in ZIKV vector competence at different geographical scales [16] [17] [18] [19] [20] [21] . However, none of these studies alone considered the entire geographical range of Ae. aegypti. Likewise, the ZIKV strains previously tested did not span the extent of ZIKV genetic diversity. Here, we established dose-response curves for eight fieldderived Ae. aegypti populations from across the global distribution of the species (Table  1) exposed to six low-passage ZIKV strains (Table 2) A total of 3,113 female Ae. aegypti were individually scored for ZIKV infection and the overall prevalence was 52.7%. Multivariate logistic regression showed that the infection status depended on a three-way interaction between infectious dose, virus strain and mosquito population (p = 0.0238), indicating that the dose-response curves differed significantly among virus-population pairs (Figure 3) . When mosquito populations were nested within their continent of origin (Asia, Africa, Americas) in the statistical model, there was a strong effect of the continent (p < 0.0001), which was mainly driven by the significantly lower susceptibility of the three African mosquito populations. This was reflected in their 50% oral infectious dose (OID 50 ), defined as the blood meal titer resulting in 50% prevalence. Across ZIKV strains, the OID 50 estimates obtained from the dose-responses curves ranged from 6.3 to 8.1 log 10 FFU/ml for the three African populations whereas they ranged from 4.7 to 6.8 log 10 FFU/ml for the five nonAfrican populations (Figure 4 ). Our data indicate that Ae. aegypti colonies of African origin are, overall, less susceptible to all ZIKV strains tested than Ae. aegypti colonies of non-African origin. Oral susceptibility does not directly translate into vector competence because the latter also depends on subsequent steps of virus dissemination and transmission. However, it is tempting to speculate that the lower susceptibility of African Ae. aegypti populations may have contributed to prevent large-scale human ZIKV outbreaks in Africa. Exceptions are Gabon where ZIKV presumably circulated in the human population in 2007 but was likely transmitted by Ae. albopictus [23] and Cabo Verde where a human ZIKV outbreak occurred in 2015 off the coast of West Africa [24] . Conversely, our data fail to provide an explanation to the lack a major human epidemic in Asia because the two Asian Ae. aegypti populations tested had similar levels of ZIKV susceptibility as American populations. The clear dichotomy observed in ZIKV susceptibility between our African and non-African Ae. aegypti colonies mirrors the two main genetic clusters of global Ae. aegypti populations [25] . Elucidating the genetic basis of this natural difference in ZIKV susceptibility could help to unravel the mechanisms of ZIKV acquisition by mosquitoes. 
